Equities research analysts at Piper Jaffray (NYSE: PJC) boosted their price target on shares of MAKO Surgical (NASDAQ: MAKO) to $35.00 in a research note to investors on Wednesday.
Separately, analysts at Canaccord Genuity initiated coverage on shares of MAKO Surgical in a research note to investors on Tuesday, June 14th. They set a “hold” rating on the stock. Also, analysts at William Blair initiated coverage on shares of MAKO Surgical in a research note to investors on Friday, May 20th. They set an “outperform” rating on the stock.
Shares of MAKO Surgical traded up 4.59% during mid-day trading on Thursday, hitting $33.229. MAKO Surgical has a 52 week low of $9.28 and a 52 week high of $35.90. The stock’s 50-day moving average is $30.08 and its 200-day moving average is $22.74. The company has a market cap of $1.361 billion.
MAKO Surgical last announced its quarterly results on Tuesday, May 3rd. The company reported ($0.27) earnings per share (EPS) for the previous quarter, missing the Thomson Reuters consensus estimate of ($0.24) EPS by $0.03. During the same quarter in the prior year, the company posted ($0.34) earnings per share. The company’s quarterly revenue was up 80.60% on a year-over-year basis. On average, analysts predict that MAKO Surgical will post $-0.21 EPS next quarter.
MAKO Surgical Corp. (MAKO) is a medical device company that markets its advanced robotic arm solution and orthopedic implants for minimally invasive orthopedic knee procedures. The Company offers MAKOplasty, a restorative surgical solution that enables orthopedic surgeons to treat patient-specific, early to mid-stage osteoarthritic knee disease. MAKOplasty is performed using the Company’s RIO Robotic Arm Interactive Orthopedic system (RIO), and its RESTORIS unicompartmental and RESTORIS MCK multi-compartmental knee implant systems. The RIO utilizes tactile guided robotic arm technology and patient-specific visualization to prepare the knee joint for the insertion and alignment of the Company’s resurfacing implants through a small incision in a minimally invasive, bone preserving and tissue sparing procedure. The Company’s RESTORIS family of knee implants is designed to enable minimally invasive restoration of one or two of the diseased compartments of the knee joint.
Stay on top of analysts’ coverage with American Banking & Market News’ daily email newsletter that provides a concise list of analysts’ upgrades, analysts’ downgrades and analysts’ price target changes for each day.Click here to register.
